85 related articles for article (PubMed ID: 21321060)
1. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Iwamura A; Fukami T; Hosomi H; Nakajima M; Yokoi T
Drug Metab Dispos; 2011 May; 39(5):838-46. PubMed ID: 21321060
[TBL] [Abstract][Full Text] [Related]
2. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Yasar U; Sain-Guven G; Yardimci Y; Kilicarslan A; Babaoglu MO; Bozkurt A
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):73-7. PubMed ID: 21332946
[TBL] [Abstract][Full Text] [Related]
3. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes.
McGinnity DF; Tucker J; Trigg S; Riley RJ
Drug Metab Dispos; 2005 Nov; 33(11):1700-7. PubMed ID: 16081671
[TBL] [Abstract][Full Text] [Related]
4. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
5. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate.
McDonald MG; Rettie AE
Chem Res Toxicol; 2007 Dec; 20(12):1833-42. PubMed ID: 18020424
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9 genetic variants and losartan oxidation in a Turkish population.
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Eur J Clin Pharmacol; 2004 Jul; 60(5):337-42. PubMed ID: 15197523
[TBL] [Abstract][Full Text] [Related]
7. Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides.
Yan Z; Li J; Huebert N; Caldwell GW; Du Y; Zhong H
Drug Metab Dispos; 2005 Jun; 33(6):706-13. PubMed ID: 15764717
[TBL] [Abstract][Full Text] [Related]
8. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
[TBL] [Abstract][Full Text] [Related]
9. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
Wennerholm A; Nordmark A; Pihlsgård M; Mahindi M; Bertilsson L; Gustafsson LL
Eur J Clin Pharmacol; 2006 Jul; 62(7):539-46. PubMed ID: 16783563
[TBL] [Abstract][Full Text] [Related]
10. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.
Sekino K; Kubota T; Okada Y; Yamada Y; Yamamoto K; Horiuchi R; Kimura K; Iga T
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):589-92. PubMed ID: 14504849
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.
Donner KM; Hiltunen TP; Suonsyrjä T; Hannila-Handelberg T; Tikkanen I; Antikainen M; Hirvonen A; Kontula K
J Hypertens; 2009 Oct; 27(10):2001-9. PubMed ID: 19593208
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a high-throughput radiometric cyp2c9 inhibition assay using tritiated diclofenac.
Di Marco A; Marcucci I; Chaudhary A; Taliani M; Laufer R
Drug Metab Dispos; 2005 Mar; 33(3):359-64. PubMed ID: 15608129
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry.
Erve JC; Vashishtha SC; DeMaio W; Talaat RE
Drug Metab Dispos; 2007 Jun; 35(6):908-16. PubMed ID: 17353349
[TBL] [Abstract][Full Text] [Related]
15. Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1.
Li AP
Chem Biol Interact; 2009 Apr; 179(1):4-8. PubMed ID: 18950609
[TBL] [Abstract][Full Text] [Related]
16. Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites.
Tang W; Stearns RA; Bandiera SM; Zhang Y; Raab C; Braun MP; Dean DC; Pang J; Leung KH; Doss GA; Strauss JR; Kwei GY; Rushmore TH; Chiu SH; Baillie TA
Drug Metab Dispos; 1999 Mar; 27(3):365-72. PubMed ID: 10064567
[TBL] [Abstract][Full Text] [Related]
17.
Sinitsina II; Boyarko AV; Temirbulatov II; Sychev DA; Akmalova KA; Sozaeva ZA; Grishina EA; Mirzaev KB; Asoskova AV; Fisenko VP
Drug Metab Pers Ther; 2023 Jun; 38(2):163-168. PubMed ID: 36580432
[TBL] [Abstract][Full Text] [Related]
18. [The inhibition of CYP2C9 isoenzyme in Cunninghamella blakesleeana AS 3. 910].
Lin LH; Huang HH; Zhang P; Zhong DF
Yao Xue Xue Bao; 2006 Oct; 41(10):967-72. PubMed ID: 17184115
[TBL] [Abstract][Full Text] [Related]
19. Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1).
Yasar U; Babaoglu MO; Bozkurt A
Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):176-9. PubMed ID: 18816302
[TBL] [Abstract][Full Text] [Related]
20. Study of recombinant cytochrome P450 2C9 activity with diclofenac by MEKC.
Konecný J; Jurica J; Tomandl J; Glatz Z
Electrophoresis; 2007 Apr; 28(8):1229-34. PubMed ID: 17377945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
